Shares of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) have been given a consensus recommendation of “Buy” by the six research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $33.00.
A number of equities research analysts have weighed in on the stock. Zacks Investment Research lowered shares of Kiniksa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, January 30th. Barclays assumed coverage on shares of Kiniksa Pharmaceuticals in a research note on Monday, March 11th. They set an “overweight” rating and a $26.00 target price for the company.
Shares of KNSA opened at $15.67 on Friday. The firm has a market cap of $857.17 million and a price-to-earnings ratio of -4.49. Kiniksa Pharmaceuticals has a 1-year low of $13.04 and a 1-year high of $32.88.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its earnings results on Thursday, May 2nd. The company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.47). As a group, equities research analysts predict that Kiniksa Pharmaceuticals will post -3.56 earnings per share for the current year.
Several large investors have recently bought and sold shares of the company. Barclays PLC increased its stake in shares of Kiniksa Pharmaceuticals by 25.7% in the 4th quarter. Barclays PLC now owns 3,054 shares of the company’s stock worth $86,000 after purchasing an additional 624 shares in the last quarter. Legal & General Group Plc purchased a new stake in shares of Kiniksa Pharmaceuticals in the 3rd quarter worth $25,000. JPMorgan Chase & Co. increased its stake in shares of Kiniksa Pharmaceuticals by 73.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,880 shares of the company’s stock worth $52,000 after purchasing an additional 1,222 shares in the last quarter. Citigroup Inc. increased its stake in shares of Kiniksa Pharmaceuticals by 145.9% in the 1st quarter. Citigroup Inc. now owns 3,426 shares of the company’s stock worth $62,000 after purchasing an additional 2,033 shares in the last quarter. Finally, Squarepoint Ops LLC increased its stake in shares of Kiniksa Pharmaceuticals by 17.7% in the 4th quarter. Squarepoint Ops LLC now owns 14,752 shares of the company’s stock worth $414,000 after purchasing an additional 2,223 shares in the last quarter. Hedge funds and other institutional investors own 24.89% of the company’s stock.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Featured Article: What is Cost of Goods Sold (COGS)?
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.